NATIONAL RESEARCH INSTITUTE Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19

NATIONAL RESEARCH INSTITUTE Announces Participation and Local Enrollment for Late Stage Global Study of mRNA Vaccine Candidate Against COVID-19

  • Mark Leibowitz, M.D., Chief Medical Officer will lead National Research Institute’s study program with Eli Francisco, Senior Project Manager
  • Potential participants can visit https://www.covidvaccinestudy.com/#about-the-study to learn more about local enrollment criteria

Los Angeles, CA, August 06, 2020— National Research Institute (NRI) today announced plans to participate as a study site for, and begin enrolling participants into, the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2, the virus causing the current global pandemic. NRI’s study site is one of more than 120 clinical investigational sites around the world that will collectively enroll up to 30,000 participants.

We are excited to be a participating research center in the development of this potentially life-saving vaccine against SARS-CoV-2. With your interest, help and community spirit, we hope that our efforts will be fruitful and contribute to reducing the impact of this virus. -Mark Leibowitz, M.D.

About the Phase 2/3 Study
The Phase 2/3 study is an event driven trial that will continue enrollment on a rolling basis, enroll up to 30,000 participants at more than 120 clinical investigational sites around the world, in non-pregnant adults 18-85 years old.

The Phase 2/3 trial is designed as a 1:1 investigational vaccine candidate to placebo, randomized, observer-blinded study to obtain safety, immune response, and efficacy data needed for regulatory review. The trial’s primary endpoints will be prevention of COVID-19 in those who have not been infected by SARS-CoV-2 prior to immunization, and prevention of COVID-19 regardless of whether participants have previously been infected by SARS-CoV-2. Secondary endpoints include prevention of severe COVID-19 in those groups.

People interested in participating in the study through the National Research Institute site can visit https://nritrials.com/covid-study/ or call 213-413-1800 to find out more.

About National Research Institute:
National Research Institute’s mission is to provide access to innovative therapies and to bring hope to our community through clinical research. Our multi-disciplinary and multi-cultural organization ensures the utmost commitment to patient care, safety, and well-being. Located in Los Angeles, Huntington Park, Panorama City, and Santa Ana, NRI has conducted clinical trials for over 30 years. Our patients have benefited from participating in the advancement of life-saving medicines, many of which are now commercially available.

National Research Institute Contacts:
Mark Leibowitz, M.D. Chief Medical Officer
Samira Moran, President & CEO
(213) 413-1800

/ Uncategorized

Share the Post

Our Response to COVID-19
X